Suppr超能文献

凝血级联反应中的渠化效应与口服抗凝剂反应的个体间变异性。一项模拟研究。

Canalization effect in the coagulation cascade and the interindividual variability of oral anticoagulant response. A simulation study.

作者信息

Corlan Alexandru D, Ross John

机构信息

University Emergency Hospital, 169 Spl Independentei, Bucharest, Romania.

出版信息

Theor Biol Med Model. 2011 Oct 12;8:37. doi: 10.1186/1742-4682-8-37.

Abstract

BACKGROUND

Increasing the predictability and reducing the rate of side effects of oral anticoagulant treatment (OAT) requires further clarification of the cause of about 50% of the interindividual variability of OAT response that is currently unaccounted for. We explore numerically the hypothesis that the effect of the interindividual expression variability of coagulation proteins, which does not usually result in a variability of the coagulation times in untreated subjects, is unmasked by OAT.

RESULTS

We developed a stochastic variant of the Hockin-Mann model of the tissue factor coagulation pathway, using literature data for the variability of coagulation protein levels in the blood of normal subjects. We simulated in vitro coagulation and estimated the Prothrombin Time and the INR across a model population. In a model of untreated subjects a "canalization effect" can be observed in that a coefficient of variation of up to 33% of each protein level results in a simulated INR of 1 with a clinically irrelevant dispersion of 0.12. When the mean and the standard deviation of vitamin-K dependent protein levels were reduced by 80%, corresponding to the usual Warfarin treatment intensity, the simulated INR was 2.98 ± 0.48, a clinically relevant dispersion, corresponding to a reduction of the canalization effect.Then we combined the Hockin-Mann stochastic model with our previously published model of population response to Warfarin, that takes into account the genetical and the phenotypical variability of Warfarin pharmacokinetics and pharmacodynamics. We used the combined model to evaluate the coagulation protein variability effect on the variability of the Warfarin dose required to reach an INR target of 2.5. The dose variance when removing the coagulation protein variability was 30% lower. The dose was mostly related to the pretreatment levels of factors VII, X, and the tissue factor pathway inhibitor (TFPI).

CONCLUSIONS

It may be worth exploring in experimental studies whether the pretreatment levels of coagulation proteins, in particular VII, X and TFPI, are predictors of the individual warfarin dose, even though, maybe due to a canalization-type effect, their effect on the INR variance in untreated subjects appears low.

摘要

背景

提高口服抗凝治疗(OAT)的可预测性并降低副作用发生率,需要进一步阐明目前尚未得到解释的约50%的OAT个体间反应变异性的原因。我们通过数值模拟探讨了以下假设:凝血蛋白个体间表达变异性的影响,在未接受治疗的个体中通常不会导致凝血时间变异性,但在OAT治疗时会显现出来。

结果

我们利用正常受试者血液中凝血蛋白水平变异性的文献数据,开发了组织因子凝血途径的Hockin-Mann模型的随机变体。我们模拟了体外凝血过程,并估算了模型群体中的凝血酶原时间和国际标准化比值(INR)。在未接受治疗的个体模型中,可以观察到一种“渠化效应”,即每种蛋白水平高达33%的变异系数会导致模拟的INR为1,且临床无关的离散度为0.12。当维生素K依赖蛋白水平的均值和标准差降低80%时,这与通常的华法林治疗强度相对应,模拟的INR为2.98±0.48,这是一个临床相关的离散度,对应于渠化效应的降低。然后,我们将Hockin-Mann随机模型与我们之前发表的华法林群体反应模型相结合,该模型考虑了华法林药代动力学和药效学的遗传和表型变异性。我们使用组合模型评估凝血蛋白变异性对达到INR目标值2.5所需华法林剂量变异性的影响。去除凝血蛋白变异性时的剂量方差降低了30%。剂量主要与因子VII、X和组织因子途径抑制剂(TFPI)的预处理水平有关。

结论

在实验研究中,探讨凝血蛋白的预处理水平,尤其是VII、X和TFPI,是否是个体华法林剂量的预测指标可能是值得的,尽管可能由于渠化型效应,它们对未接受治疗个体的INR方差的影响似乎较小。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c85/3215663/262665f45f29/1742-4682-8-37-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验